Opciones terapéuticas disponibles ante la falla al tratamiento anti-TNF en pacientes con Enfermedad Inflamatoria Intestinal
Gastroenterol. latinoam; 34 (2), 2023
Results: 23
Corticoides en el manejo de la Enfermedad Inflamatoria Intestinal: se propone un uso racional
Rev. méd. Chile; 150 (5), 2022
Evaluation of factors affecting the frequency and clinical course of COVID-19 in patients using anti-TNF-alpha agents
Rev. Assoc. Med. Bras. (1992, Impr.); 67 (9), 2021
SUMMARY OBJECTIVES: Patients being treated with anti-tumor necrosis factor-alpha (anti-TNF-alpha) agents were reported to have better prognosis related to COVID-19. We evaluated the factors affecting the frequency, clinical course, and outcome of COVID-19 in patients treated with anti-TNF-alpha agents. ...
COVID-19/diagnóstico, Comorbilidad, Hospitalización, Enfermedades Inflamatorias del Intestino/tratamiento farmacológico, Persona de Mediana Edad, Pronóstico, Estudios Retrospectivos, Enfermedades Reumáticas/tratamiento farmacológico, Inhibidores del Factor de Necrosis Tumoral/administración & dosificación
Terapia biológica en pacientes embarazadas con enfermedad inflamatoria intestinal: una visión ampliada sobre su uso
Rev. méd. Chile; 149 (4), 2021
Indicadores do estado corporal do ferro e indicadores de inflamação durante o tratamento da doença inflamatória intestinal em crianças e adolescentes
Arq. gastroenterol; 58 (1), 2021
ABSTRACT BACKGROUND: The treatment of patients with inflammatory bowel disease (IBD) consists of the induction and maintenance remission of the disease. Iron status indicators would be useful for the diagnosis of iron deficiency anemia, whereas the inflammation indicators would be for the diagnosis of ...
Assistência à saúde de pessoas com doenças colorretais no sistema público a perspectiva do usuário
Trata-se de um estudo de desenho misto, do tipo sequencial explanatório, sendo que na etapa quantitativa descritiva e transversal, objetivou-se analisar a demanda de atendimento de assistência de pessoas com queixas colorretais em Unidades de Saúde da Família no Sistema Único de Saúde (SUS); e na e...
Utilização da monitorização terapêutica com níveis séricos de infliximabe nas doenças inflamatórias intestinais: um algoritmo simplificado baseado em evidências
Arq. gastroenterol; 57 (4), 2020
ABSTRACT Therapeutic drug monitoring (TDM) of infliximab (IFX) has been recognized as an important strategy in the management of secondary loss of response to this agent, guiding clinical decision-making in the management of inflammatory bowel diseases (IBD). Although most of the data on the application ...
Fatores associados com a escolha da terapia nos pacientes com doença inflamatória intestinal no Brasil
Arq. gastroenterol; 57 (4), 2020
BACKGROUND: Biological therapy and new drugs have revolutionized the treatment of inflammatory bowel disease. Ideally, the choice of medication should be a shared decision with the patient, aiming at greater satisfaction, compliance, and consequently, favorable clinical outcome. OBJECTIVE: This study a...
Administración Oral, Brasil, Colitis Ulcerosa/tratamiento farmacológico, Estudios Transversales, Fármacos Gastrointestinales/administración & dosificación, Fármacos Gastrointestinales/uso terapéutico, Enfermedades Inflamatorias del Intestino/tratamiento farmacológico, Inyecciones Subcutáneas/estadística & datos numéricos, Persona de Mediana Edad, Prioridad del Paciente, Satisfacción del Paciente, Encuestas y Cuestionarios, Terapia Biológica
Potential impact of COVID-19 on colorectal disease management
J. coloproctol. (Rio J., Impr.); 40 (3), 2020
Abstract The current recommendations for management of colorectal diseases are still evolving, due to the limited experience on this issue. As the new coronavirus can be transmitted through breath droplets, by contact and orofecally, there is no consensus of how this fact may affect the investigation and...
Taxas de descontinuação do tratamento após a troca de um biológico originador por um biossimilar em pacientes com doenças inflamatórias intestinais: revisão sistemática e metanálise
Arq. gastroenterol; 57 (3), 2020
ABSTRACT BACKGROUND: Biologics have revolutionized the treatment of inflammatory bowel disease (IBD). However, these drugs had a significant influence on treatment-related costs, which resulted in the development of biosimilars. OBJECTIVE: This systematic review and meta-analysis aimed to evaluate th...